Cookies on the BTG website

We use cookies to ensure that we give you the best experience on our website.

If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the BTG website.

Find out more


Email to a friend
Email to a friend

* Required

Our Programmes

Our most advanced development programmes are listed below. In addition, we have assets in development with our partners, as well as a number of out-licensed marketed products for which the company receives royalties on sales.

BTG is currently enrolling patients for three Phase 3 clinical trials using TheraSphere®, EPOCH (TS 102), STOP-HCC (TS 103) and YES-P (TS 104).

Development Programme Target Indication Status


Hepatocellular carcinoma (HCC) and 2nd line metastatic colorectal cancer (mCRC)

Phase III

Embolisation and chemoembolisation beads

Hepatocellular carcinoma (HCC) and 3rd line metastatic colorectal cancer (mCRC)

Combination of investigator-initiated and registration studies planned

Our approved products
our critical care

We sell our approved Specialty Pharmaceutical, Interventional Oncology and Interventional Vascular products in the US through our dedicated sales teams and through distributors in other territories.

Our history of partnering
our history of partnering

We have a strong track record of partnering products successfully and a pipeline of partnered programmes, some of which we believe may have significant commercial potential.